Related Experiment Videos
[Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?]
Schweizerische Medizinische Wochenschrift
|December 13, 1986
Summary
1,25-dihydroxycholecalciferol (1,25[OH]2D3), a vitamin D3 metabolite, showed no significant benefit in reducing bone marrow fibrosis in idiopathic myelofibrosis patients. Further research is needed to explore its therapeutic potential in hematological disorders.
Area of Science:
- Endocrinology
- Hematology
- Cell Biology
Context:
- 1,25-dihydroxycholecalciferol (1,25[OH]2D3) is the active metabolite of vitamin D3.
- It exhibits antiproliferative effects on megakaryocytes in vitro.
- Potential modulation of collagen metabolism by megakaryocyte/monocyte interactions.
Purpose:
- To evaluate the clinical efficacy of 1,25(OH)2D3 in patients with idiopathic myelofibrosis.
Summary:
- Four patients with idiopathic myelofibrosis received daily doses of 1,25(OH)2D3 (0.006–0.016 microgram/kg).
- One patient died from asthenia; three were observed for over a year.
- All patients required regular transfusions, and bone marrow biopsies showed no reduction in fibrosis.
Impact:
- 1,25(OH)2D3 treatment did not demonstrate a clinical benefit in reducing bone marrow fibrosis in this small cohort.
- The findings suggest limited efficacy of 1,25(OH)2D3 for idiopathic myelofibrosis management.
- Further investigation into vitamin D metabolites in myelofibrosis may be warranted.